Cyproterone acetate: new advice to minimise risk of meningioma
Risk of meningioma with cyproterone acetate increases with increasing cumulative dose.
Remain vigilant for signs and symptoms of bleeding complications during treatment with DOACs (apixaban, dabigatran, edoxaban, rivaroxaban), especially in patients with increased bleeding risks.
Letters and drug alerts sent to healthcare professionals in May 2020
A summary of letters and drug alerts recently sent to healthcare professionals.